- About
- PsychU For You
- Topics
- Events
- Content
Identification of Agitation in Patients with Dementia due to Alzheimer’s Disease: Perspectives from the Primary Care Provider
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Identification of Agitation in Patients with Dementia due to Alzheimer’s Disease: Perspectives from the Primary Care Provider
Join us for a discussion with Dr. C. Brendan Montano, as he shares his perspective from the primary care setting on identifying and responding to agitation associated with dementia due to Alzheimer’s disease. The discussion will explore the prevalence and burden of agitation in Alzheimer’s dementia, recognition of agitation symptoms, as well as the use of the AASC™, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders. This tool is designed to assist caregivers in recognizing AAD and starting the conversation with their medical provider.
C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
MoreDr. Montano is Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut, where he also holds a private practice in internal medicine, specializing in preventative medicine and mood disorders. In addition, he is an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut.
Amaka Onyereri, PharmD, BCPS (OPDC)
Medical Science Liaison
MoreAmaka Onyereri received her bachelor’s degree in general science and Doctor of Pharmacy degree from Oregon State University/Oregon Health Sciences University. Her passion for patient care led her to practice clinically as a community pharmacist where she served patients for close to 20 years in different capacities as a staff pharmacist, pharmacy manager and pharmacy clinical services manager. As a Pharmacy Clinical Services Manager, Amaka spearheaded various clinical and patient care initiatives such as immunizations, medication therapy management, point of care testing, and most recently a long-acting injectables pilot for antipsychotics.
Lindsay Teliska, PhD (OPDC)
Medical Science Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc.
Dr. C. Brendan Montano is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Amaka Onyereri is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Lindsay Teliska is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
November 2024 US.CORP.X.24.00325Related Events
Registration
- PsychU For You
